Wealthfront Advisers LLC Acquires Shares of 20,250 DexCom, Inc. $DXCM

Wealthfront Advisers LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, HoldingsChannel reports. The fund acquired 20,250 shares of the medical device company’s stock, valued at approximately $1,364,000.

Other institutional investors have also modified their holdings of the company. Reflection Asset Management acquired a new position in shares of DexCom during the 4th quarter worth about $25,000. Ascentis Independent Advisors purchased a new position in DexCom in the 1st quarter valued at about $25,000. MCF Advisors LLC acquired a new stake in DexCom in the 4th quarter worth about $32,000. Wellington Grp LLC boosted its holdings in DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after buying an additional 475 shares during the last quarter. Finally, DV Equities LLC purchased a new stake in DexCom during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Up 2.3%

DXCM stock opened at $92.34 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average of $77.49 and a two-hundred day moving average of $70.94. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.56. The company has a market cap of $34.85 billion, a price-to-earnings ratio of 36.50, a PEG ratio of 1.52 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.48 EPS. As a group, analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the sale, the insider directly owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 73,035 shares of company stock worth $5,446,673. 0.28% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on DXCM. Raymond James Financial reissued a “strong-buy” rating and set a $94.00 target price on shares of DexCom in a report on Friday, July 31st. Argus boosted their price target on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Benchmark boosted their price target on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group set a $90.00 price objective on DexCom and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Bank of America decreased their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.